Pfizer’s Elrexfio improves progression-free survival in Phase 3 multiple myeloma trial
PFE•Pfizer said Elrexfio met the primary endpoint in the Phase 3 MagnetisMM-32 trial, reducing the risk of disease progression or death compared with standard regimens in relapsed or refractory multiple myeloma. The company plans to seek regulatory review for potential use in earlier treatment lines.
1. Trial met primary endpoint
Pfizer said Elrexfio met the primary endpoint in the Phase 3 MagnetisMM-32 trial, outperforming standard regimens for patients with relapsed or refractory multiple myeloma who had previously received anti-CD38 therapy and lenalidomide. Treatment reduced the risk of disease progression or death.
2. Safety and next steps
No new safety signals emerged, though severe infections were more frequent with Elrexfio than with comparator treatments. Pfizer plans global regulatory submissions; detailed results are expected to be presented at a future medical meeting and submitted for publication.
